Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - Theoretical approach

Pharmaceutical Research

Volumn 16, Issue 2, 1999, Pages 225-231

  Ito, Kiyomi ^a   Kusuhara, Hiroyuki ^b   Sugiyama, Yuichi ^b  

^a KITASATO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

CYP3A4; Diffusion model; Drug interaction; Oral absorption; P glycoprotein

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; ERYTHROMYCIN; GLYCOPROTEIN P; KETOCONAZOLE; RIFAMPICIN;

ARTICLE; CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DIFFUSION; DRUG METABOLISM; DRUG PENETRATION; DUODENUM; ENZYME INHIBITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; JEJUNUM; MATHEMATICAL ANALYSIS; MICROSOME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0033007704     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018872207437     Document Type: Article

References (30)

1. 1. J. C. Kolars, W. M. Awni, R. M. Merion, and P. B. Watkins. First-pass metabolism of cyclosporin by the gut. Lancet 338:1488-1490 (1991).
2. 2. J. C. Kolars, P. Schmiedlin-Ren, J. D. Schuetz, C. Fang, and P. B. Watkins. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90:1871-1878 (1992).
3. 3. K. E. Thummel, D. O'Shea, M. F. Paine, D. D. Shen, K. L. Kunze, J. D. Perkins, and G. R. Wilkinson. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59:491-502 (1996).
4. 4. I. De Waziers, P. H. Cugnenc, C. S. Yang, J.-P. Leroux, and P. H. Beaune. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253:387-394 (1990).
5. 5. M. F. Hebert, J. P. Roberts, T. Prueksaritanont, and L. Z. Benet. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52:453-457 (1992).
6. 6. D. Y. Gomez, V. J. Wacher, S. J. Tomlanovich, M. F. Hebert, and L. Z. Benet. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther. 58:15-19 (1995).
7. 7. S. K. Gupta, A. Bakran, R. W. G. Johnson, and M. Rowland. Cyclosporin-erythromycin interaction in renal transplant patients. Br. J. Clin. Pharmacol. 27:475-481 (1989).
8. 8. C.-Y. Wu, L. Z. Benet, M. F. Hebert, S. K. Gupta, M. Rowland, D. Y. Gomez, and V. J. Wacher. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin. Pharmacol. Ther. 58:492-497 (1995).
9. 9. H. Saitoh and B. J. Aungst. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm. Res. 12:1304-1310 (1995).
10. 10. T. Terao, E. Hisanaga, Y. Sai, I. Tamai, and A. Tsuji. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J. Pharm. Pharmacol. 48:1083-1089 (1996).
11. 11. V. J. Wacher, C.-Y. Wu, and L. Z. Benet. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. 13:129-134 (1995).
12. 12. E. G. Schuetz, W. T. Beck, and J. D. Schuetz. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49:311-318 (1996).
13. 13. K. S. Lown, R. R. Mayo, A. B. Leichtman, H. L. Hsiao, D. K. Turgeon, P. Schmiedlin-Ren, M. B. Brown, W. Guo, S. J. Rossi, L. Z. Benet, and P. B. Watkins. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62:248-260 (1997).
14. 14. Y. Zhang, X. Guo, E. T. Lin, and L. Z. Benet. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. Drug Metab. Dispos. 26:360-366 (1998).
15. 15. I. Komiya, J. Y. Park, A. Kamani, N. F. H. Ho, and W. I. Higuchi. Quantitative mechanistic studies in simultaneous fluid flow and intestinal absorption using steroids as model solutes. Int. J. Pharm. 4:249-262 (1980).
16. 16. K. Sathirakul, H. Suzuki, K. Yasuda, M. Hanano, and Y. Sugiyama. Construction of a physiologically based pharmacokinetic model to describe the hepatobiliary excretion process of ligands: quantitative estimation of intracellular diffusion. Biol. Pharm. Bull. 16:273-279 (1993).
17. 17. M. D. Levitt, J. K. Furne, A. Strocchi, B. W. Anderson, and D. G. Levitt. Physiological measurements of luminal stirring in the dog and human small bowel. J. Clin. Invest. 86:1540-1547 (1990).
18. 18. T. Iwatsubo, N. Hirota, T. Ooie, H. Suzuki, and Y. Sugiyama. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm. Drug Dispos. 17:273-310 (1996).
19. 19. T. Iwatsubo, N. Hirota, T. Ooie, H. Suzuki, N. Shimada, K. Chiba, T. Ishizaki, C. E. Green, C. A. Tyson, and Y. Sugiyama. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73:147-171 (1997).
20. 20. K. Ito, T. Iwatsubo, S. Kanamitsu, Y. Nakajima, and Y. Sugiyama. Quantitative prediction of in vi vo drug clearance and drug interactions from in vitro data on metabolism together with binding and transport. Annu. Rev. Pharmacol. Toxicol. 38:461-499 (1998).
21. 21. Y. Sugiyama, T. Iwatsubo, K. Ueda, and K. Ito. Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration. J. Toxicol. Sci. 21:309-316 (1996).
22. 22. K. Ito, T. Iwatsubo, S. Kanamitsu, K. Ueda, H. Suzuki, and Y. Sugiyama. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol. Rev. 50:387-411 (1998).
23. 23. R. J. Stock, E. V. Cilento, and R. S. McCuskey. A quantitative study of fluorescein isothiocyanate-dextran transport in the microcirculation of the isolated perfused rat liver. Hepatology 9:75-82 (1989).
24. 24. A. B. Fulton. How crowded is the cytoplasm? Cell 30:345-347 (1982).
25. 25. M. Chiba, M. Hensleigh, and J. H. Lin. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem. Pharmacol. 53:1187-1195 (1997).
26. 26. M. F. Paine, M. Khalighi, J. M. Fisher, D. D. Shen, K. L. Kunze, C. L. Marsh, J. D. Perkins, and K. E. Thummel. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 283:1552-1562 (1997).
27. 27. P. Artursson and J. Karlsson. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Comm. 175:880-885 (1991).
28. 28. S. Yamashita, Y. Tanaka, Y. Endoh, Y. Taki, T. Sakane, T. Nadai, and H. Sezaki. Analysis of drug permeation across Caco-2 monolayer: implication for predicting in vivo drug absorption. Pharm. Res. 14:486-491 (1997).
29. 29. C. L. Crespi, B. W. Penman, and M. Hu. Development of Caco2 cells expressing high levels of cDNA-derived cytochrome P4503A4. Pharm. Res. 13:1635-1641 (1996).
30. 3. Mol. Pharmacol. 51:741-754 (1997).